Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-231-4 | CAS number: 68526-83-0
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Additional information
90 -day subchronic oral dosing in rats to isooctanol (CAS number 68526 -83 -0; 100, 300, and 700mg/kg/d) and isotridecanol (CAS number 68526 -86 -3; 100, 300, 1000mg/kg/d) resulted in nonadverse hepatic effects (hepatocellular hypertrophy correlated with increased liver weights) and non-human relevant changes to the kidneys in male rats. Exposure to isotridecanol (CAS number 68526 -86 -3) also resulted in nonadverse hepatic effects (hepatocellular hypertrophy correlated with increased liver weights), nonadverse lung and thyroid findings, and non-human relevant changes to the kidneys.
Oral
Additionally, repeat oral dosing studies with related (C6, C8, C9, C10, and C13) linear alcohols indicate minimal effects (US HPV, 2006; OECD SIAR, 2006). In repeated oral dosing studies with related (C8, C9, C10, C13) linear alcohols there were minimal hepatic effects (i.e., elevated liver weight and hepatic peroxisomal enzyme levels along with changes in serum lipid levels), but testicular weight was unaffected. The NOAELs from these studies were set at the limit dose of 1mM/kg/day (130, 144, 168, and 184 mg/kg/day for C8, C9, C10, C13, respectively)
Dermal
Male and female rabbits were subjected to a repeated dose of either 0.5 or 2.5 ml/kg body weight isooctanol. Undiluted control and test material were applied to intact skin of the animals once daily for a total of 10 applications with a 1 day rest period between the first and second applications, and a 2 day rest period between the third and fourth and eighth and ninth applications. Repeated applications of isooctanol produced moderate or marked degree of dermal irritation. The irritation was characterized by slight or moderate erythema, slight or moderate edema, and slight to marked atonia and desquamation. In addition, two of the low level animals showed slight necrosis, and all of the high level animals showed fissuring and a coriaceous condition of the skin. There were no adverse systemic effects noted.
Inhalation
No data signs of toxicity were observed in rats inhaling 180 ppm isooctanol (maximal achievable concentration) 6 hours/day for 13 days (Gage, 1970). No maternal toxicity was seen after inhalation for 19 days of near saturated vapor concentrations of 840 ppm 1-hexanol, 200 ppm 2-EH, 65 ppm 1-octanol, 25 ppm 1-nonanol, or 15 ppm 1-decanol in a developmental toxicity study using pregnant rats (Nelson et al., 1990).
Justification for classification or non-classification
No classification for repeated dose toxicity is indicated according to the general classification and labeling requirements for dangerous substances and preparations (Directive 67-548-EEC) or the classification, labeling and packaging (CLP) regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
